Evidence for the Use of Epoprostenol to Treat Raynaud’s Phenomenon With or Without Digital Ulcers

“

Common tertiary drug resources provide conflicting recommendations relating to the choice of prostanoid drug, dose, and duration of therapy in patients with Raynaud's Disease when more conservative treatments and pharmacotherapy options have failed. To complicate matters, the most commonly used prostanoid for this purpose worldwide, injectable iloprost, is not commercially available in the United States. This review provides evidence-based guidance on the use of epoprostenol pharmacotherapy for the management of Raynaud's Disease.

”